In this video playlist, I show you how to solve different math problems for Algebra, Geometry, Algebra 2, and Pre-Calculus.

I make short, to-the-point online math tutorials. I struggled with math growing up and have been able to use those ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research ...

Total Revenue (Q4 2025): $3.2 billion, a 10% increase compared to Q4 2024. Total Revenue (Full Year 2025): $12 billion, a 9% increase versus 2024. CF Revenue Growth (Full Year 2025): 7% globally.

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex to seek US approval after promising late-stage results for kidney drug Vertex Pharmaceuticals said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Vertex Pharma ceuticals CEO Reshma Kewalramani bought a big chunk of the biotech’s stock earlier this month. The move, her first open-market purchase in years, appears to be a show of confidence in ...

Wagner reiterated Vertex's 2025 total revenue guidance of $11.85 billion to $12 billion, representing approximately 8% growth at midpoint. This outlook reflects ongoing ALYFTREK and CASGEVY launches, ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term ...